Tranexamic Acid Exporter and Supplier from India
We supply Tranexamic Acid as IV ampoules (500 mg/5 mL and 1000 mg/10 mL) and as 500 mg and 250 mg tablets to importers, distributors and tender buyers across Africa, the GCC, South East Asia and Latin America. This antifibrinolytic sits on the WHO Essential Medicines List for haemorrhage, so it moves through EmONC, maternal-health and trauma procurement in real volume. As a merchant-exporter trading since 2003, M Care consolidates the acute-care ampoule and the oral menorrhagia pack from WHO-GMP manufacturing lines and ships them against a single purchase order.
Buying Tranexamic Acid in bulk for haemorrhage programmes
Demand for Tranexamic Acid splits cleanly into two channels, and we quote each one separately. The IV ampoule is an acute-haemorrhage line: it feeds obstetric-emergency (postpartum haemorrhage) and trauma/surgical tenders where the WOMAN and CRASH-2 trials anchor the case for early treatment. The oral tablet is a chronic outpatient line for heavy menstrual bleeding, dental cover in haemophilia and angioedema. We hold both so a distributor can serve hospital pharmacy and retail from one supplier rather than splitting the enquiry.
Acute ampoule for EmONC and trauma tenders
500 mg/5 mL and 1000 mg/10 mL glass ampoules for labour wards, operating theatres and emergency departments. This is the SKU national maternal-health and trauma programmes call for by the box.
Oral pack for menorrhagia and dental cover
500 mg and 250 mg tablets in blister strips for outpatient heavy menstrual bleeding, dental extraction in haemophilia and hereditary angioedema. A separate demand curve from the injection.
MOQ set by the batch-release minimum
Order quantity is set by the source manufacturer's batch-release minimum, not an arbitrary floor we invent. Tell us your ampoule and tablet split and we size the run against a live production slot.
Pricing quoted per pack, per market
Price on request. Ampoule and tablet are quoted separately and by destination, because freight, ambient handling and registration overheads differ across your import market.
Tranexamic Acid at a glance: forms, strengths and class
Active ingredient
Tranexamic acid, a synthetic lysine analogue that blocks plasminogen from binding to fibrin, slowing clot breakdown (antifibrinolysis).
Strengths stocked
IV: 500 mg/5 mL and 1000 mg/10 mL ampoules (100 mg/mL). Oral: 500 mg and 250 mg tablets. Fixed-dose oral combinations with mefenamic acid are available on enquiry.
Formulation and handling
Room-temperature product, no cold chain. Ampoules travel as a standard ambient pharma line, which keeps landed cost and last-mile risk low for African and GCC lanes.
Regulatory class
Prescription (Rx) antifibrinolytic haemostatic. ATC B02AA02. On the WHO Essential Medicines List, added in 2011 for haemorrhage and extended in 2019 for postpartum haemorrhage.
Reference brands
Reference innovator and generic brands in this molecule include Trapic (Sun Pharma), Texakind (Mankind) and Cyklokapron. Named for buyer identification only, not as a retail offer.
Therapy area
Haematology and biologicals: haemostasis and bleeding control, spanning obstetric emergency, trauma surgery and gynaecology.
Buyers we serve for Tranexamic Acid
The molecule reaches very different desks depending on the form, so the enquiries we handle rarely look alike. Here is who typically writes to us.
Government and EmONC tender buyers
Central medical stores and maternal-health programmes procuring the IV ampoule for postpartum-haemorrhage protocols. These lots need CoPP, batch traceability and dossier support to clear the tender.
Hospital and trauma-network distributors
Importers stocking operating theatres, emergency departments and surgical units where early IV tranexamic acid is part of the bleeding-control pathway.
Retail and wholesale distributors
Partners moving the 500 mg and 250 mg oral packs for heavy menstrual bleeding and dental use through pharmacy channels.
NGO and humanitarian procurers
Relief and field-health buyers who need an ambient, non-cold-chain haemostatic that ships and stores simply in low-infrastructure settings.
Safety-critical notes for procurement teams
This is reference context for professional buyers, not clinical instruction. Product labelling in your destination market governs the final indications, contraindications and warnings. Tranexamic acid is contraindicated in active intravascular clotting and thromboembolic disease and in patients with a history of venous or arterial thrombosis, because slowing clot breakdown raises thrombotic risk. It is also contraindicated in subarachnoid haemorrhage (a risk of cerebral oedema and infarction has been reported) and, for long-term oral use, in patients with acquired defective colour vision, since colour vision is a monitoring endpoint for retinal toxicity.
Because the drug is renally cleared, the dose is reduced in renal impairment to avoid accumulation. High intravenous doses, particularly in cardiac surgery and after inadvertent neuraxial injection, have been associated with seizures, which is why the acute ampoule belongs in a controlled hospital setting. Concomitant use with combined hormonal contraceptives warrants caution given the additive thrombotic signal. For acute bleeding, both the WOMAN (postpartum) and CRASH-2 (trauma) trials found the survival benefit depends on treatment within roughly 3 hours, which shapes how emergency stocks are positioned rather than how the product is stored.
Written for professional buyers and importers, not as medical advice. Prescribing decisions sit with the treating clinician and the approved label in your market.
Export and registration documents we compile
We prepare the paperwork that lets your regulatory affairs team file Tranexamic Acid in your market, working alongside the manufacturer. M Care's own quality credential is ISO 9001:2015; the WHO-GMP and any WHO-PQ status belongs to the manufacturing line we supply from.
CoPP and free-sale certificate
Certificate of Pharmaceutical Product in WHO format plus free-sale documentation, sourced from the manufacturer for your national registration file.
CTD dossier support
We compile the CTD dossier alongside you, coordinating Module 3 quality data with the manufacturer for your import licence submission.
Manufacturer GMP evidence
Valid WHO-GMP certificate and manufacturing licence for the production line, so your authority can confirm the source is GMP-compliant.
Batch and stability records
Certificate of Analysis per batch, method of analysis and stability data covering the ambient shelf life of the ampoule and tablet.
Shipping and legalisation set
Invoice, packing list, certificate of origin and, where required, consular or apostille legalisation to clear customs in your market.
Molecules buyers source alongside Tranexamic Acid.
Enoxaparin
Low-molecular-weight heparin anticoagulant, the opposite side of the clotting balance from this antifibrinolytic.
Human Albumin
Plasma volume expander used alongside haemostatics in major haemorrhage and resuscitation.
Epoetin Alfa
Erythropoietin that rebuilds red cell mass after the blood loss tranexamic acid helps control.
How ordering works.
- Send your enquiry Tell us the form (IV ampoule or oral tablet), strengths, quantities and destination market. Splitting acute versus oral demand up front lets us quote accurately.
- Receive quote and documents We confirm price on request, the batch-release minimum from the source line and the registration document set your market needs.
- Approve the pro forma On your confirmation we lock the production slot, share artwork and pack proofs, and align labelling with your regulatory requirements.
- Dispatch and track We ship as an ambient pharma consignment with full export documentation and keep you updated to landed delivery.
Tranexamic Acid supply, the specific questions.
Do you supply Tranexamic Acid as both injection and tablet?
Yes. We stock the IV ampoule in 500 mg/5 mL and 1000 mg/10 mL for acute postpartum, trauma and surgical bleeding, and the oral tablet in 500 mg and 250 mg for heavy menstrual bleeding, dental cover and angioedema. Buyers commonly order both under one purchase order so hospital and retail channels are served from a single supplier.
Is Tranexamic Acid on the WHO Essential Medicines List?
Yes. It carries ATC code B02AA02 and appears on the WHO Essential Medicines List, added in 2011 for haemorrhage and extended in 2019 to cover postpartum haemorrhage. That EML status is why the ampoule features in EmONC and maternal-health tenders across our export markets.
What is the minimum order quantity?
There is no fixed floor we invent. The minimum is set by the source manufacturer's batch-release minimum for the specific strength and pack. Share your ampoule and tablet split and destination and we will size the order against a live production slot.
Which regulatory documents do you provide for registration?
We compile the CoPP, free-sale certificate, manufacturer WHO-GMP evidence, batch Certificate of Analysis, stability data and the full shipping and legalisation set. We also compile the CTD dossier alongside your regulatory team. M Care's own quality system is ISO 9001:2015; WHO-GMP and any WHO-PQ status belongs to the manufacturing line.
Does the injection need a cold chain?
No. Tranexamic Acid ampoules and tablets are ambient, room-temperature products with no cold-chain requirement. That keeps landed cost and last-mile handling straightforward, which matters for African, GCC and field-health lanes where refrigeration is a constraint.
What is the significance of the 3-hour treatment window for tender buyers?
In acute bleeding the survival benefit is time-critical: the WOMAN trial (postpartum haemorrhage) and CRASH-2 trial (trauma) both found tranexamic acid works best given within about 3 hours. For a procurement team this shapes stock positioning, keeping the ampoule close to labour wards and emergency departments rather than affecting how it is stored, since the product itself is stable at ambient temperature.
Can you name reference brands for identification?
For buyer identification, reference brands in this molecule include Trapic (Sun Pharma), Texakind (Mankind) and Cyklokapron. We supply generic tranexamic acid from GMP lines; brand names are given only so you can match the product to what your market already recognises, not as a retail offer of a specific brand.
Request a Tranexamic Acid quote
Send us your strengths, forms and destination market for Tranexamic Acid ampoules and tablets. We reply with price on request, the batch-release minimum from the source line and the registration document set your market requires.